Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate
Phase 2ActiveDevelopment Stage
Aggressive Non-Hodgkin Lymphoma
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Indolent Non-Hodgkin Lymphoma, Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
Jan 2, 2019 → Dec 31, 2026
About Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate
Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate is a phase 2 stage product being developed by Bristol Myers Squibb for Aggressive Non-Hodgkin Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03749018. Target conditions include Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03749018 | Phase 2 | Active |
Competing Products
11 competing products in Aggressive Non-Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy | Johnson & Johnson | Phase 2 | 52 |
| Loncastuximab Tesirine and Epcoritamab | AbbVie | Phase 2 | 52 |
| Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib | AstraZeneca | Phase 2 | 52 |
| Midostaurin | Novartis | Phase 2 | 52 |
| Imatinib | Novartis | Phase 2 | 52 |
| Bendamustine and subcutaneous rituximab | Roche | Phase 2 | 52 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 1/2 | 40 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| cemiplimab + odronextamab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| PRT2527 + Zanubrutinib + Venetoclax | Prelude Therapeutics | Phase 1 | 25 |